Announcement PDF Proposed issue of securities Update Summary Entity name ALTERITY THERAPEUTICS LIMITED Announcement Type Update to previous announcement Date of this announcement 5/1/2024 Reason for update to a previous announcement Proposed issue of securities approved by shareholders at EGM held 29 December 2023. Refer to next page for full details of the announcement Proposed issue of securities 1 / 10 Proposed issue of securities Part 1 - Entity and announcement details 1.1 Name of +Entity ALTERITY THERAPEUTICS LIMITED We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules. If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation). 1.2 Registered Number Type Registration Number ABN 37080699065 1.3 ASX issuer code ATH 1.4 The announcement is Update/amendment to previous announcement 1.4a Reason for update to a previous announcement Proposed issue of securities approved by shareholders at EGM held 29 December 2023. 1.4b Date of previous announcement to this update 18/12/2023 1.5 Date of this announcement 5/1/2024 1.6 The Proposed issue is: An offer of +securities under a +securities purchase plan Proposed issue of securities 2 / 10 Proposed issue of securities Part 4 - Details of proposed offer under securities purchase plan Part 4A - Conditions 4A.1 Do any external approvals need to be obtained or other conditions satisfied before the offer of +securities under the +securities purchase plan issue can proceed on an unconditional basis? Yes 4A.1a Conditions Approval/Condition Date for determination +Security holder approval 29/12/2023 Is the date estimated or actual? Actual Comments Proposed issue of securities 3 / 10 ** Approval received/condition met? Yes Proposed issue of securities Part 4B - Offer details Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued ASX +security code and description ATH : ORDINARY FULLY PAID Will the proposed issue of this +security include an offer of attaching +securities? Yes Details of +securities proposed to be issued ASX +security code and description ATH : ORDINARY FULLY PAID Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted 571,428,571 Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)? No Will the offer be conditional on applications for a maximum number of +securities being received or a maximum amount being raised (i.e. a maximum subscription condition)? No Will individual security holders be required to accept the offer for a minimum number or value of +securities (i.e. a minimum acceptance condition)? No Will individual security holders be limited to accepting the offer for a maximum number or value of +securities (i.e. a maximum acceptance condition)? Yes Is the maximum acceptance unit based or dollar based? Dollar based ($) Please enter the maximum acceptance value $ 30,000 Describe all the applicable parcels available for this offer in number of securities or dollar value Parcels are yet to be determined and will be advised in the offer document. Offer price details Proposed issue of securities 4 / 10 Proposed issue of securities Has the offer price been determined? Yes In what currency will the offer be made? What is the offer price per +security? AUD - Australian Dollar AUD 0.00350 Oversubscription & Scale back details Will a scale back be applied if the offer is over-subscribed? Yes Describe the scale back arrangements The Company reserves the right to scale back applications under the SPP at its discretion, if required. The Company may scale back the number of new shares that will be allotted under the SPP and the Eligible Shareholder may be allocated fewer new shares than the number applied for. If there is a scale back, a proportionate refund to the amount subscribed for will be paid by the Company to the Shareholders shortly after the Closing Date. Interest will not be paid on money refunded. Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? Yes Attaching +Security The proposed attaching security can only be of an 'Existing class' (additional +securities in a class that is already quoted or recorded by ASX) New class Attaching +Security - New class (+securities in a class that is not yet quoted or recorded by ASX) Details of attaching +securities proposed to be issued ISIN Code (if Issuer is a foreign company and +securities are non CDIs) Have you received confirmation from ASX that the terms Will the entity be seeking quotation of the 'new' class of of the proposed +securities are appropriate and +securities on ASX? No equitable under listing rule 6.1? No ASX +security code +Security description New class-code to be confirmed Short-dated option +Security type Options Offer ratio (ratio of attaching securities at which the new +securities will be issued) The quantity of attaching +securities to be issued Proposed issue of securities For a given quantity of the new +securities issued 5 / 10 Proposed issue of securities The quantity of attaching +securities to be issued For a given quantity of the new +securities issued 1 1 What will be done with fractional entitlements? Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted Fractions rounded down to the nearest whole number or fractions disregarded 571,428,571 Offer price details Has the offer price been determined? No How and when will the offer price be determined? Free attaching short-dated option per Placement announcement 22 November 2023. Please confirm whether the offer of the attaching +securities is a separate offer to the offer pursuant to the +security purchase plan No Please confirm whether the attaching +securities are being offered under a +disclosure document or +PDS Yes Oversubscription & Scale back details Will a scale back be applied if the offer is over-subscribed? Yes Describe the scale back arrangements The Company reserves the right to scale back applications under the SPP at its discretion, if required. The Company may scale back the number of new shares that will be allotted under the SPP and the Eligible Shareholder may be allocated fewer new shares than the number applied for. If there is a scale back, a proportionate refund to the amount subscribed for will be paid by the Company to the Shareholders shortly after the Closing Date. Interest will not be paid on money refunded. Will all the +securities issued in this class rank equally in all respects from their issue date? Yes Options details +Security currency AUD - Australian Dollar Exercise price Expiry date AUD 0.0070 31/8/2024 Details of the type of +security that will be issued if the option is exercised ATH : ORDINARY FULLY PAID Proposed issue of securities 6 / 10 Proposed issue of securities Number of securities that will be issued if the option is exercised One ATH ordinary fully paid share Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement. https://alteritytherapeutics.com/investor-overview/asx-announcements/ Details of attaching +securities proposed to be issued ISIN Code (if Issuer is a foreign company and +securities are non CDIs) Have you received confirmation from ASX that the terms Will the entity be seeking quotation of the 'new' class of of the proposed +securities are appropriate and +securities on ASX? Yes equitable under listing rule 6.1? No ASX +security code +Security description New class-code to be confirmed Long-dated option +Security type Options Offer ratio (ratio of attaching securities at which the new +securities will be issued) The quantity of attaching +securities to be issued For a given quantity of the new +securities issued 1 3 What will be done with fractional entitlements? Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted Fractions rounded down to the nearest whole number or fractions disregarded 190,476,191 Offer price details Has the offer price been determined? No How and when will the offer price be determined? One (1) free attaching long-dated option per three (3) shares issued under SPP per Placement announcement 22 November 2023. Please confirm whether the offer of the attaching +securities is a separate offer to the offer pursuant to the +security purchase plan No Please confirm whether the attaching +securities are being offered under a +disclosure document or +PDS Yes Oversubscription & Scale back details Will a scale back be applied if the offer is over-subscribed? Proposed issue of securities 7 / 10 Proposed issue of securities Yes Describe the scale back arrangements The Company reserves the right to scale back applications under the SPP at its discretion, if required. The Company may scale back the number of new shares that will be allotted under the SPP and the Eligible Shareholder may be allocated fewer new shares than the number applied for. If there is a scale back, a proportionate refund to the amount subscribed for will be paid by the Company to the Shareholders shortly after the Closing Date. Interest will not be paid on money refunded. Will all the +securities issued in this class rank equally in all respects from their issue date? Yes Options details +Security currency AUD - Australian Dollar Exercise price Expiry date AUD 0.0100 31/8/2026 Details of the type of +security that will be issued if the option is exercised ATH : ORDINARY FULLY PAID Number of securities that will be issued if the option is exercised One ATH ordinary fully paid share Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement. https://alteritytherapeutics.com/investor-overview/asx-announcements/ Part 4C - Timetable 4C.1 Date of announcement of +security purchase plan 22/11/2023 4C.2 +Record date 21/11/2023 4C.3 Date on which offer documents will be made available to investors 10/1/2024 4C.4 Offer open date 10/1/2024 Proposed issue of securities 8 / 10 Proposed issue of securities 4C.5 Offer closing date 25/1/2024 4C.7 +Issue date and last day for entity to announce results of +security purchase plan offer 2/2/2024 Part 4D - Listing Rule requirements 4D.1 Does the offer under the +securities purchase plan meet all of the requirements of listing rule 7.2 exception 5 or do you have a waiver from those requirements? No 4D.1a Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? No 4D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? No Part 4E - Fees and expenses 4E.1 Will there be a lead manager or broker to the proposed offer? No 4E.2 Is the proposed offer to be underwritten? No 4E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission? No 4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer Proposed issue of securities 9 / 10 Proposed issue of securities Part 4F - Further Information 4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue The use of proceeds from this financing will provide ongoing funding of Alterity's Phase 2 clinical trials in MSA, planning for a Phase 3 clinical trial, continuing discovery and research efforts and general working capital. 4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful? No 4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer All countries except Australia and New Zealand 4F.3 URL on the entity's website where investors can download information about the proposed offer https://alteritytherapeutics.com/investor-overview/asx-announcements/ 4F.4 Any other information the entity wishes to provide about the proposed offer Proposed issue of securities 10 / 10